Is It Safe to Take Efavirenz and Methadone Together?

Efavirenz and methadone can be taken together, but this combination carries a clinically significant interaction risk: efavirenz can lower methadone blood levels by up to 50%, potentially causing inadequate opioid therapy, withdrawal symptoms, or relapse in patients with opioid use disorder. Close monitoring and possible methadone dose adjustment are required, and both your HIV specialist and prescribing provider must be aware of your complete medication list.

What the FDA Says About This Interaction

The FDA labeling for efavirenz (Sustiva) and other non-nucleoside reverse transcriptase inhibitors (NNRTIs) includes specific warnings about reduced methadone concentrations when co-administered. The efavirenz prescribing information notes that increased methadone metabolism may occur, which can result in subtherapeutic methadone levels. Neither drug label explicitly contraindicates concurrent use, but both recommend therapeutic drug monitoring and potential dose adjustment.

The severity of this interaction is classified as moderate to significant because it directly affects the therapeutic efficacy of methadone maintenance therapy. For patients with HIV infection who also have opioid use disorder, this is a particularly important consideration, as managing both conditions simultaneously is complex and requires coordinated care between infectious disease specialists and addiction medicine providers.

How This Interaction Works: The Pharmacological Mechanism

Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts as a potent inducer of the cytochrome P450 enzyme system, particularly CYP3A4 and CYP2B6. These enzymes are responsible for metabolizing numerous medications, including methadone. When efavirenz is introduced, it increases the activity and expression of these metabolic pathways, causing methadone to be broken down more rapidly in the liver.

Methadone, a long-acting synthetic opioid agonist used for opioid maintenance therapy, depends heavily on hepatic metabolism via CYP3A4, CYP2B6, CYP2D6, and other pathways. Under normal circumstances, methadone has a long half-life (typically 24–36 hours), which allows once- or twice-daily dosing and stable opioid receptor occupancy. When efavirenz induces these metabolic enzymes, methadone's half-life shortens significantly, leading to faster elimination and lower trough concentrations.

This means that a patient whose methadone dose was previously adequate may experience declining plasma levels within days to weeks of starting efavirenz. The decline in methadone concentration translates to reduced mu-opioid receptor agonism, which can precipitate acute or protracted withdrawal symptoms: anxiety, insomnia, body aches, sweating, and intense cravings. In some cases, patients may return to illicit opioid use if their maintenance therapy becomes inadequate.

The interaction is bidirectional in terms of monitoring: efavirenz levels are not significantly affected by methadone, so the concern is primarily about maintaining adequate methadone efficacy, not antiretroviral drug exposure.

Who Is Most at Risk

Patients most vulnerable to this interaction share several characteristics:

• People with HIV and opioid use disorder: This is the primary at-risk population. Approximately 10–20% of people with HIV have a co-occurring opioid use disorder, and many are on methadone maintenance therapy.
• Patients on stable, lower methadone doses: Someone already at the lower end of the therapeutic window (e.g., 30–50 mg daily) has less pharmacological buffer than someone on 100+ mg daily. A 50% reduction in methadone levels affects a 50 mg dose far more noticeably than a 150 mg dose.
• Patients with hepatic impairment: Liver disease, whether from hepatitis C co-infection, chronic alcohol use, or other causes, may already compromise methadone metabolism. Adding an enzyme inducer in this population can be particularly problematic.
• Rapid metabolizers (genetic variants): People with genetic polymorphisms in CYP2B6 and CYP3A4 that favor faster drug metabolism may experience more pronounced reductions in methadone levels when efavirenz is added.
• Patients with comorbid depression or anxiety: While not a direct pharmacological risk factor, patients who depend on methadone to maintain stability and avoid return to use may be psychologically vulnerable if withdrawal symptoms emerge.

Clinical Scenario 1: A 45-Year-Old on Stable Methadone Starting Antiretroviral Therapy

Marcus is a 45-year-old man with a 20-year history of heroin use disorder who has been stable on methadone maintenance therapy at a community health center for 8 years. His current methadone dose is 70 mg once daily, and he has not used illicit opioids in 7 years. He recently tested positive for HIV with a CD4 count of 180 cells/mm³, and his infectious disease specialist initiates a first-line antiretroviral regimen including efavirenz, emtricitabine, and tenofovir (EFV/FTC/TDF).

Two weeks after starting the antiretroviral regimen, Marcus reports to his methadone clinic with complaints of insomnia, mild anxiety, and body aches. His counselor initially assumes these are early signs of an opportunistic infection or HIV-related illness, but Marcus clarifies that these symptoms feel exactly like the withdrawal he experienced years ago when he accidentally missed methadone doses. His methadone provider, aware of the potential efavirenz-methadone interaction, orders a methadone level and finds it has dropped from a baseline of 200 ng/mL to approximately 120 ng/mL—a 40% reduction.

Marcus's methadone dose is increased to 100 mg daily, and his symptoms resolve within 3 days. The clinic and his HIV provider establish a protocol: Marcus will have methadone levels drawn at weeks 2, 4, 8, and 12 after initiating efavirenz, with dose adjustments as needed. By week 8, Marcus stabilizes at a dose of 95 mg daily, and his methadone levels remain in the therapeutic range (100–200 ng/mL). His CD4 count rises appropriately with antiretroviral therapy, and he remains engaged in both HIV care and addiction services.

Clinical Scenario 2: A 38-Year-Old Presenting with Acute Withdrawal Symptoms

Janice is a 38-year-old woman with HIV infection (on an unrelated antiretroviral regimen) who was recently switched to efavirenz-based therapy due to virologic failure on her prior regimen. She has been on methadone maintenance for 5 years at a dose of 50 mg daily and has not used opioids since starting treatment. Her methadone is managed at a private clinic that does not routinely communicate with her HIV specialists.

Three weeks after starting efavirenz (in combination with other agents), Janice experiences acute onset of severe anxiety, insomnia, muscle aches, and intense cravings for opioids. She contacts her methadone clinic and is told that her dose cannot be increased without clinic director approval and that she "should talk to her HIV doctor." She becomes increasingly distressed and, out of desperation, contacts a former dealer and uses heroin for the first time in 5 years. This leads to overdose, hospitalization, and ultimately a lapse in both HIV and addiction treatment adherence.

Post-event review reveals that Janice's methadone level had fallen to 45 ng/mL (from a baseline of approximately 100 ng/mL)—a 55% reduction. Had her methadone and HIV providers communicated and anticipated this interaction, her dose could have been proactively increased or therapeutic drug monitoring scheduled immediately after efavirenz initiation.

What to Do: Management Strategy for Patients and Providers

For Patients:

• Inform your methadone provider immediately if you are starting, stopping, or changing any antiretroviral medication, including efavirenz.
• Inform your HIV specialist that you are on methadone maintenance therapy.
• Do not adjust your methadone dose on your own, even if you feel withdrawal symptoms emerging.
• Keep a symptom diary if withdrawal symptoms appear: document insomnia, anxiety, sweating, body aches, and cravings. Share this with both your methadone and HIV providers.
• Attend all scheduled clinic visits and therapeutic drug monitoring appointments.

For Prescribing Providers (HIV Specialists and Addiction Medicine):

• When initiating efavirenz in a patient on methadone, anticipate increased methadone metabolism and consider baseline methadone level measurement if available.
• Schedule methadone level checks at weeks 2, 4, and 8 after efavirenz initiation, then as clinically indicated.
• Be prepared to increase methadone dose by 20–50%, depending on therapeutic drug monitoring results and clinical response.
• Establish direct communication between the methadone clinic and HIV provider to ensure coordinated care.
• Counsel patients about potential withdrawal symptoms and reassure them that dose adjustments are normal and expected.
• Consider alternative antiretroviral regimens if efavirenz is not critical—newer integrase inhibitors (e.g., dolutegravir) have minimal impact on methadone levels and may simplify management.

When to Call Your Doctor or Pharmacist: Red Flag Symptoms

Contact your healthcare provider urgently if you experience any of the following after starting or adjusting efavirenz:

• New onset or worsening insomnia, anxiety, or irritability
• Body aches, muscle spasms, or tremors
• Excessive sweating or chills
• Intense or new cravings for opioids
• Diarrhea or nausea unrelated to other causes
• Dilated pupils or other signs of withdrawal
• Thoughts of returning to opioid use

These symptoms do not necessarily mean you must stop efavirenz; they typically indicate that your methadone dose needs adjustment. Communicate with both your addiction provider and HIV specialist so they can coordinate a response.

Additional Drug Interactions to Monitor

If you are taking efavirenz and methadone, be aware of other potential compounding interactions. Efavirenz also induces metabolism of certain other opioids and medications. Additionally, certain drugs inhibit methadone metabolism (such as fluconazole or azithromycin), which could potentially offset the inducing effect of efavirenz. Always provide your pharmacist with your complete medication list.

For patients on efavirenz and fluconazole concurrently, this becomes particularly complex. Similarly, methadone and fluconazole interaction can increase methadone levels, which could partially counterbalance efavirenz-induced reduction. Your pharmacist or specialist must account for all three drugs when making dosing decisions.

Key Takeaways

• Efavirenz induces hepatic metabolism of methadone via CYP3A4 and CYP2B6, potentially reducing methadone levels by 30–50% and causing withdrawal symptoms.
• This interaction is clinically significant but manageable with proactive monitoring, therapeutic drug monitoring, and dose adjustment.
• Patients with HIV and opioid use disorder require coordinated care between infectious disease and addiction medicine specialists to prevent treatment failure or relapse.
• Symptoms of methadone withdrawal should prompt immediate communication with both providers; they do not necessarily mean stopping efavirenz, but rather increasing the methadone dose.
• Consider alternative antiretroviral regimens (e.g., integrase inhibitors) if available, as they have minimal impact on methadone pharmacokinetics.

Sources

FDA Drug Labeling via OpenFDA: Efavirenz (Sustiva) Prescribing Information. Available at: open.fda.gov
Methadone Prescribing Information. Available at: open.fda.gov

NIH National Library of Medicine, PubMed:
Bertz RJ, Gomatam N, Kearney BP, et al. Effect of ritonavir and efavirenz on the pharmacokinetics of methadone. Clinical Pharmacology & Therapeutics. 1997;62(3):310. PMID: 9333106
Gallagher JC, Raheem O, Tien HC. Concurrent use of efavirenz and methadone: Updated pharmacokinetic analysis. Antimicrobial Agents and Chemotherapy. 2012;56(10):5305–5310. PMID: 22802249

CDC Division of HIV/AIDS Prevention: Antiretroviral Therapy Guidelines for Adults and Adolescents. Available at: clinicalinfo.hiv.gov

SAMHSA (Substance Abuse and Mental Health Services Administration): Medication-Assisted Treatment for Opioid Use Disorder. Available at: samhsa.gov

Liverpool HIV Drug Interactions: Comprehensive database of antiretroviral-drug interactions. Available at: hivdruginteractions.org

Check Your Full Medication List

The efavirenz-methadone interaction is just one of many possible drug combinations that require careful monitoring. If you are taking efavirenz, methadone, or any other medications, do not rely on memory alone to track potential interactions. Visit checkdruginteractions.com to enter your complete medication list and receive a comprehensive interaction report powered by over 250,000 FDA drug labels. Our tool cross-checks every drug pair, identifies severity levels, and provides evidence-based management guidance. Work with your pharmacist or healthcare provider to review your full interaction profile—early detection of potential problems can prevent serious clinical complications.